Evaluation of the effects of nicotineamide mononucleotide administered intravenously to healthy subjects.
Not Applicable
Recruiting
- Conditions
- healthy subjects
- Registration Number
- JPRN-UMIN000049123
- Lead Sponsor
- TOKYO GINZA WELLNESS & AGING CLINIC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
(1) The subjects who suffer from serious cerebrovascular, cardiac, metabolic, hepatic, renal, gastrointestinal, or cancer diseases (2) The subjects who habe an extremely irregular diet (3) The subjects with serious allegic diseases (4) Pregnant or possibly pregnant (5) The subject who are currently participating in other clinical research or clinical trials, or those who habe participated in other clinical research or clinicl trals within the past three months (6) The subjects who are judged as unsuitable for the study by the principal investigator or subinvestigator (7) The subjects who lack judgment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety of intravenous administration of NMN.
- Secondary Outcome Measures
Name Time Method